Sionna Therapeutics Inc. (SION)
SION trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | SION on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2025 |
| SEC CIK | 0002036042 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Recent IPO: no annual report filed yet.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued." | 10-Q 2026-11-10 |
| Cash and burn | $83.9M cash; operating cash flow -$19.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 45,235,568 (2026-10-30); 44,628,788 a year earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-03-02 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $134.3M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$32.4M | -$18.7M | $83.9M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | Not filed | -$29.9M | -$22.2M | $63.3M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2026 2026-03-31 | Not filed | -$26.8M | -$21.8M | $63.3M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q4 2025 2025-12-31 | Not filed | -$20.4M | -$16.6M | $58.5M | No debt tags | Needs four quarters | 10-K 2026-03-02 |
| Q3 2025 2025-09-30 | Not filed | -$20.3M | -$15.2M | $50.8M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | Not filed | -$18.1M | -$18.2M | $41.0M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2025 2025-03-31 | Not filed | -$16.5M | -$16.3M | $82.7M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q4 2024 2024-12-31 | Not filed | -$15.8M | -$11.8M | $37.8M | No debt tags | Needs four quarters | 10-K 2026-03-02 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-03-02 |
| Latest annual report | 10-K | 2026-03-02 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEFA14A | 2026-04-27 |
Source: SEC EDGAR submissions feed, 234 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.5% |
| 1 month | -24.0% |
| 3 months | -49.1% |
| Year to date | -91.9% |
| 1 year | -90.7% |
| From 52-week high | -93.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RNA | Atrium Therapeutics Inc. | $6.43 | -14.38% | $138.7M |
| MGNX | MacroGenics Inc. | $2.17 | -1.36% | $138.7M |
| MSLE | Satellos Bioscience Inc. | $6.47 | -2.34% | $137.3M |
| VRXA | Veraxa Biotech AG | $1.04 | -5.86% | $147.8M |
| MENS | Jyong Biotech Ltd. | $1.77 | +0.57% | $134.6M |
| ABEO | Abeona Therapeutics Inc. | $2.60 | +7.44% | $148.6M |
| NTHI | NeOnc Technologies Holdings Inc. | $4.54 | -7.54% | $131.0M |
| CNTN | Canton Strategic Holdings Inc. | $1.64 | -4.09% | $130.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier